Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients. GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways and is used in several hematologic and solid‑tumor indications. - Chronic myeloid leukemia (CML): provides disease control by inhibiting BCR‑ABL signaling. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): promotes remission through targeted kinase blockade. - Gastrointestinal stromal tumor (GIST): reduces tumor size by targeting c‑KIT and PDGFR pathways.

Adverse reactions vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the lower limbs. - Muscle cramps: intermittent painful contractions. - Fatigue: generalized tiredness. - Diarrhea: loose stools, sometimes watery. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: marked reduction in white blood cells. - Cardiac failure: reduced cardiac output or heart failure symptoms. - Pulmonary hypertension: increased pressure in lung arteries. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly. - Blood count monitoring: perform complete blood counts weekly during the first month. - Liver function tests: check hepatic enzymes before start and periodically thereafter. - Cardiac assessment: evaluate ejection fraction in patients with pre‑existing heart disease. - Drug interactions: avoid strong CYP3A4 inhibitors unless benefits outweigh risks. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Imatinib may interact with several co‑administered medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and toxicity. - Concomitant use with other BCR‑ABL inhibitors: additive toxicity risk. - QT‑prolonging agents (e.g., quinidine, sotalol): can exacerbate cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic exposure. - Acid‑suppressive therapy (e.g., proton‑pump inhibitors): may modestly affect absorption. - Warfarin: monitor INR as imatinib can alter anticoagulant effect.